Skip to main content
. Author manuscript; available in PMC: 2009 Sep 2.
Published in final edited form as: J Am Coll Cardiol. 2008 Jul 2;52(10):869–881. doi: 10.1016/j.jacc.2008.04.055

Figure 6. Pioglitazone decreases LPS-induced soluble VCAM-1 in PPARα+/+ but not PPARα−/− mice in vivo.

Figure 6

PPARα+/+ and PPARα−/− mice were treated with pioglitazone or vehicle alone before LPS injection (n = 9/genotype as in Methods). sVCAM-1 levels in PPARα+/+ and PPARα−/− mice are shown at baseline (*p<0.007 PPARα−/− vs. PPARα+/+ mice) and after LPS injection in mice treated with either vehicle or pioglitazone (PPARα+/+, n=9, #p<0.002 LPS/vehicle vs. vehicle; ‡p<0.01 pioglitazone/LPS vs. vehicle/LPS) and in PPARα−/− mice (n=9, †p<0.05 vehicle/LPS vs. vehicle; (NS) non-significant pioglitazone/LPS vs. vehicle/LPS, significance determined using Mann-Whitney test). The mean serum sVCAM-1 concentration of each group ± SD is shown.